Clinical trial for Schizophenia Disorder
Official title Exercise and Olanzapine-samidorphan
ClinicalTrials.gov ID: NCT06740890
What this study is testing
What is Olanzapine-samidorphan + exercise?
An investigational combination of olanzapine-samidorphan and aerobic exercise being studied as a potential treatment for schizophrenia and related disorders. Olanzapine is designed to block dopamine and serotonin receptors, while samidorphan is designed to act as an opioid receptor antagonist that may reduce weight gain.
Also referred to as Olz/Sam.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how adding four weeks of aerobic exercise affects people who are already taking olanzapine and samidorphan for their mental health condition.
- Who it's for
- Adults diagnosed with schizophrenia, schizoaffective disorder, or bipolar I, II, or NOS disorder.
- What's involved
- Participants will take olanzapine and samidorphan for eight weeks and will do supervised aerobic exercise for four weeks, with study visits and basic health checks.
- Time commitment
- The trial lasts about eight weeks and includes regular study visits during that time.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Age between 18-65, inclusive at Visit 1.
- DSM-V diagnosis of schizophrenia or schizoaffective or Bipolar I/II/NOS disorder at Visit 1.
- Body Mass Index (BMI) of 18.0-40.0 kg/m2, inclusive, at Visits 1 and 2.
- Willing to provide informed consent at Visit 1.
- Medically and psychiatrically stable for study participation at Visit 1.
You likely can't join if
- Positive drug screen for opioids, phencyclidine, amphetamine/ methamphetamine, or cocaine at Visit 1 or Visit 2.
- Diagnosis of moderate or severe substance use disorder, anorexia nervosa, bulimia, binge eating disorder or any other clinically significant eating...
- EKG abnormality that is clinically significant including a QT interval \> 450 msec for men and \> 470 msec for women, as corrected by the Fridericia...
- Use of olanzapine+samidorphan for any reason in the last six months prior to Visit 1, any history of poor or inadequate response to treatment with...
- Taken opioid agonists (e.g., codeine, oxycodone, tramadol, or morphine) within the 14 days prior to Visit 1 and/or anticipates a need to take opioid...
- Pregnant or breast feeding women. Women of child-bearing potential must have a negative serum beta-hCG pregnancy test at Visit 1 and a negative urine...
See the full eligibility criteria
- Age between 18-65, inclusive at Visit 1.
- DSM-V diagnosis of schizophrenia or schizoaffective or Bipolar I/II/NOS disorder at Visit 1.
- Body Mass Index (BMI) of 18.0-40.0 kg/m2, inclusive, at Visits 1 and 2.
- Willing to provide informed consent at Visit 1.
- Medically and psychiatrically stable for study participation at Visit 1.
- Responsive to an antipsychotic treatment (other than clozapine) in the past 5 years prior to Visit 1.
- Can benefit from participation in this study and has a reason to participate, such as inadequate how well it works on current treatment, side effects on current treatment, desire to start olanzapine-samidorphan or try...
- Maintained a stable body weight (change \< 5%) for at least 3 months prior to Visit 1.
- Willing to use qualified methods of contraception (listed in section 5.3) for the study duration (for women of childbearing potential only) (assessed at Visit 1 and Visit 2).
- Positive drug screen for opioids, phencyclidine, amphetamine/ methamphetamine, or cocaine at Visit 1 or Visit 2.
- Diagnosis of moderate or severe substance use disorder, anorexia nervosa, bulimia, binge eating disorder or any other clinically significant eating disorder at Visit 1.
- EKG abnormality that is clinically significant including a QT interval \> 450 msec for men and \> 470 msec for women, as corrected by the Fridericia formula (QTcF) at Visit 1.
- Use of olanzapine+samidorphan for any reason in the last six months prior to Visit 1, any history of poor or inadequate response to treatment with olanzapine or no justifiable reason to expect improvement on olanzapine...
- Taken opioid agonists (e.g., codeine, oxycodone, tramadol, or morphine) within the 14 days prior to Visit 1 and/or anticipates a need to take opioid medication during the study period (e.g., planned surgery), or has...
- Pregnant or breast feeding women. Women of child-bearing potential must have a negative serum beta-hCG pregnancy test at Visit 1 and a negative urine pregnancy test at Visit 2.
- Clinically significant hypotension or hypertension not stabilized on medical therapy.
- Unstable thyroid dysfunction in the past 6 months (e.g., hypothyroidism, hyperthyroidism, or thyroiditis that was untreated, or discovered and treatment was initiated within the 6 months prior to screening).
- Personal or family history of neuroleptic malignant syndrome, has a history of clinically significant extrapyramidal symptoms when taking olanzapine, or has had clinically significant tardive dyskinesia.
- History of seizure disorder or a condition associated with seizures (except history of febrile seizures).
- History of brain tumor, subdural hematoma, stroke or any other clinically significant neurological condition within the 12 months prior to Visit 1.
- Head trauma with loss of consciousness within the 12 months prior to Visit 1.
- Active, acute or chronic CNS infection.
- Clinically significant cardiac arrhythmia, cardiomyopathy, a cardiac conduction defect, or a history of myocardial infarction or unstable angina within 6 months prior to Visit 1.
- Currently taking any contraindicated medications as per the approved labeling for Olz-Sam (see section 6.5 for details) at Visit 1 and Visit 2.
- people with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 3 months prior to Visit 1 or current at Visit 2
- Inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss at Visit 1.
- Joined a weight management program or had significant changes in diet or exercise regimen within 6 weeks prior to Visit 1 or plans to join a weight management program during the study as assessed at Visit 1.
- History of diabetes (assessed at Visit 1).
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value \> 2 times the upper limit of the laboratory normal reference range
- Absolute neutrophil count (ANC) \<1.5 x 10\^3 μL
- Platelet count \< 75 x 10\^3 uL
- Serum creatinine \> 1.5 mg/dL
- Dyslipidemia, defined for this study as total fasting cholesterol \> 280 mg/dL or fasting triglycerides \> 500 mg/dL
- Hemoglobin A1c (HbA1c) \> 6.0%
- Fasting plasma glucose \> 126 mg/dL (7.0 mmol/L)
- Is not fit for the trial in the opinion of the investigator at Visit 1 and Visit 2.
The study team makes the final eligibility decision.
Where it is enrolling
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at New York, New York, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.